This presentation is dedicated to exploring the Pioneer Antibody Discovery Platform. Learn how you can partner with Bio-Rad to overcome the challenges you face in antibody discovery for biotherapeutics.
Bio-Rad presents the new antibody discovery service specifically designed to develop best-in-class biologic candidates. The Pioneer Platform features a state-of-the-art phage display library engineered to include more than 200 billion unique sequences and capable of identifying high-affinity antibody candidates using our newly developed, proprietary SpyDisplay selection technology.
Technical expert Francisco Ylera, PhD, introduces the technology involved in the Pioneer Antibody Discovery Platform and Paul Royle, PhD, then explains what to expect from this tailored service.Speak with a specialist
Paul Royle, PhD (Technical Sales Manager for Custom Antibody Services at Bio-Rad; UK) discusses the newly developed Bio-Rad antibody library in this interview. He addresses how Pioneer Platform differs from other commercially available antibody libraries and what this means for scientists conducting therapeutic antibody discovery.Find out more by reading the article
Bio-Rad’s expansive antibody library platform sets the stage for an innovative and pioneering approach to biotherapeutic antibody discovery.
Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology, such as phage display, have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen.
The Pioneer Antibody Discovery Platform is a new state-of-the-art therapeutic antibody generation service. With decades of phage display and antibody engineering experience, Bio-Rad™ provides cutting-edge tools for lead generation discovery and optimization to bring you the best-in-class biologic candidates. By tailoring our services to your specific needs, our team of specialists accelerates and simplifies your journey to identify functional biologics for your target of interest..
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the Pioneer Antibody Discovery Platform, a new antibody discovery service specifically designed to develop best-in-class biologic candidates.
The complete remission from advanced rectal cancer observed in all patients who participated in a small clinical trial echoed strongly in global news channels earlier in 2022 (Cercek et al., 2022). “I believe this is the first time this has happened in the history of cancer” is how the NEJM study lead, Dr L Diaz, an oncologist at Memorial Sloan Kettering Cancer Center, framed the study’s success to the New York Times.
Bio-Rad recently announced the launch of their new antibody discovery service. Designed specifically for developing best-in-class biologic candidates, the Pioneer Antibody Discovery Platform is optimized to find suitable candidates for drug development.
Join us on a journey to the forefront of therapeutic antibody development. In this podcast, you'll gain insights into how scientists and specialists at Bio-Rad are revolutionizing the biopharmaceutical industry through their customized approach to antibody discovery.